Update on Ustekinumab for Psoriasis

被引：0

作者：

Nia J.K. ^{[1
]}

Hashim P.W. ^{[1
]}

Kimmel G. ^{[1
]}

Aleisa A. ^{[1
]}

Farahani A.C. ^{[1
]}

Lebwohl M.G. ^{[1
]}

机构：

[1] Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 E. 98th Street, New York, 10029, NY

来源：

Current Dermatology Reports | 2017年 / 6卷 / 1期

关键词：

Biologic; Efficacy; Infection; MACE; Malignancy; Psoriasis; Ustekinumab;

D O I：

10.1007/s13671-017-0167-8

中图分类号：

学科分类号：

摘要：

Purpose of Review: This review will highlight the latest data on ustekinumab, as well as provide anecdotal evidence and insight into unanswered questions regarding its safety and the populations’ best suited for its use. Recent Findings: In numerous clinical trials, ustekinumab has been found to be safe and efficacious. Many targeted psoriasis medications affecting the same pathway have since been approved as treatments. Recent data supports the notion that ustekinumab does not increase risk of cardiovascular events, and in fact, may be protective against them. Summary: Targeted biologic medications for psoriasis have given insight into the complex interactions of the immune system. With these medications, patients suffering from psoriasis can now achieve up to 100 % skin clearance. Ustekinumab (Stelara®; Janssen Biotech, Inc.), a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and IL 23, was approved in 2009 for the treatment of moderate-to-severe plaque psoriasis and has become a standard against which other biologics are tested. Future studies should be directed toward exploring the long-term safety of ustekinumab, as well as efficacy of ustekinumab beyond 5 years of therapy. © 2017, Springer Science+Business Media New York.

引用

页码：29 / 34

页数：5

共 41 条

[1]

Lebwohl M., Biologics for psoriasis: a translational research success story, J Invest Dermatol., 135, 5, pp. 1205-1207, (2015)

[2]

Bartlett B.L., Tyring S.K., Ustekinumab for chronic plaque psoriasis, Lancet, 371, 9625, pp. 1639-1640, (2008)

[3]

Au S.C., Madani A., Alhaddad M., Alkofide M., Gottlieb A.B., Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center, J Drugs Dermatol., 12, 8, pp. 861-866, (2013)

[4]

Abuabara K., Wan J., Troxel A.B., Shin D.B., Van Voorhees A.S., Bebo B.F., Et al., Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis, J Am Acad Dermatol, 68, 2, pp. 262-269, (2013)

[5]

Famenini S., Wu J.J., The efficacy of ustekinumab in psoriasis, J Drugs Dermatol., 12, 3, pp. 317-320, (2013)

[6]

Benson J.M., Peritt D., Scallon B.J., Heavner G.A., Shealy D.J., Giles-Komar J.M., Et al., Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders, MAbs, 3, 6, pp. 535-545, (2011)

[7]

Harden J.L., Krueger J.G., Bowcock A.M., The immunogenetics of psoriasis: a comprehensive review, J Autoimmun, 64, pp. 66-73, (2015)

[8]

Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Et al., Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13, 5, pp. 715-725, (2000)

[9]

Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A., Circulating Th17, Th22, and Th1 cells are increased in psoriasis, J Invest Dermatol, 130, 5, pp. 1373-1383, (2010)

[10]

Benson J.M., Sachs C.W., Treacy G., Zhou H., Pendley C.E., Brodmerkel C.M., Et al., Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab, Nat Biotechnol, 29, 7, pp. 615-624, (2011)

← 1 2 3 4 5 →